Michael E Feigin
Overview
Explore the profile of Michael E Feigin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1694
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crawford K, Humphrey K, Cortes E, Wang J, Feigin M, Witkiewicz A, et al.
bioRxiv
. 2025 Feb;
PMID: 39974881
Purpose: We previously identified an oncogenic role for the transcription factor HNF1A in pancreatic ductal adenocarcinoma (PDAC). However, the role of HNF1A in the metastatic progression of PDAC remains unknown...
2.
Venkat S, Feigin M
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339391
Human tumors are characterized by extensive intratumoral transcriptional variability within the cancer cell and stromal compartments. This variation drives phenotypic heterogeneity, producing cell states with differential pro- and anti-tumorigenic properties....
3.
Alahmari A, Chaubey A, Jonnakuti V, Tisdale A, Schwarz C, Cornwell A, et al.
RNA
. 2024 Jan;
30(3):281-297.
PMID: 38191171
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with limited effective treatment options, potentiating the importance of uncovering novel drug targets. Here, we target cleavage and polyadenylation specificity factor 3...
4.
Cornwell A, Tisdale A, Venkat S, Maraszek K, Alahmari A, George A, et al.
Clin Cancer Res
. 2023 Aug;
29(18):3793-3812.
PMID: 37587561
Purpose: This research investigates the association between benzodiazepines (BZD) and cancer patient survival outcomes, the pancreatic cancer tumor microenvironment, and cancer-associated fibroblast (CAF) signaling. Experimental Design: Multivariate Cox regression modeling...
5.
Doepner M, Lee I, Natale C, Brathwaite R, Venkat S, Kim S, et al.
Sci Adv
. 2022 Sep;
8(35):eabn4007.
PMID: 36054350
Melanoma risk is 30 times higher in people with lightly pigmented skin versus darkly pigmented skin. Using primary human melanocytes representing the full human skin pigment continuum and preclinical melanoma...
6.
Alam S, Zunic A, Venkat S, Feigin M, Atanassov B
Mol Cancer Res
. 2022 Aug;
20(12):1751-1762.
PMID: 36001804
Implications: As a deubiquitinating enzyme, USP27X is a druggable target. Our study illuminates new avenues for therapeutic intervention in CCND1-driven cancers.
7.
Venkat S, Alahmari A, Feigin M
Trends Cancer
. 2021 Feb;
7(7):594-605.
PMID: 33618999
Pancreatic ductal adenocarcinoma (PDAC) remains a devastating disease with a poor prognosis. The functional consequences of common genetic aberrations and their roles in treatment strategies have been extensively reviewed. In...
8.
Cornwell A, Feigin M
Trends Pharmacol Sci
. 2020 Nov;
41(12):1006-1022.
PMID: 33198923
G protein-coupled receptors (GPCRs) are the most common class of therapeutic targets, accounting for ~35% of all FDA-approved drugs. Cancer patients receive numerous medications not only to combat cancer but...
9.
Venkat S, Tisdale A, Schwarz J, Alahmari A, Maurer H, Olive K, et al.
Genome Res
. 2020 Feb;
30(3):347-360.
PMID: 32029502
Alternative polyadenylation (APA) is a gene regulatory process that dictates mRNA 3'-UTR length, resulting in changes in mRNA stability and localization. APA is frequently disrupted in cancer and promotes tumorigenesis...
10.
Insel P, Sriram K, Wiley S, Wilderman A, Katakia T, McCann T, et al.
Front Pharmacol
. 2018 Jun;
9:431.
PMID: 29872392
G protein-coupled receptors (GPCRs), the largest family of targets for approved drugs, are rarely targeted for cancer treatment, except for certain endocrine and hormone-responsive tumors. Limited knowledge regarding GPCR expression...